GlassScriptPhysician profile
Eric Joseph Lai
NPI 1942592522
$22,804.20
in general payments reported to CMS, 2019-2025
25 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $86.35 · 2021: $480 · 2022: $2,607 · 2023: $2,547 · 2024: $1,497 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $4,524 · Travel and Lodging: $2,208 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,654.00 |
| Food and Beverage | $4,524.28 |
| Travel and Lodging | $2,208.09 |
| Education | $103.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,498.71 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $6,676.61 | 2025 | |
| Calliditas Therapeutics US INC. | $3,693.11 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $856.01 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $834.55 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $433.11 | 2022-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $421.62 | 2023-2025 | Jynarque |
| Travere Therapeutics, INC. | $371.41 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $295.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $239.91 | 2020-2025 | Acthar |
| Novo Nordisk INC | $206.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $199.27 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $157.58 | 2022-2025 | Lupkynis |
| Ardelyx, INC. | $138.07 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.41 | 2024 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $111.98 | 2024-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $103.18 | 2023-2025 | Rayaldee |
| Regeneron Healthcare Solutions, INC. | $99.76 | 2024 | Eylea Hd |
| Ani Pharmaceuticals, INC. | $81.97 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $72.06 | 2021-2022 | |
| Horizon Therapeutics Plc | $62.14 | 2022-2023 | Krystexxa |
| Daiichi Sankyo INC. | $43.38 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $31.42 | 2025 | Empaveli |
| Akebia Therapeutics INC | $31.10 | 2019-2022 | |
| Lilly USA, LLC | $24.42 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.